Pharmaceutical parenteral composition of dual GLP1/2 agonist
The present invention relates to pharmaceutical compositions suitable for parenteral administration in human subjects. In particular, the present invention relates to isotonic pharmaceutical compositions for parenteral administration.
1 . An isotonic parenteral pharmaceutical composition, comprising:
a. at least about 1 mg/mL of one or more GLP-1/GLP-2 dual agonist, wherein the one or more GLP-1/GLP-2 dual agonist is Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)QAARDFIAWLIQHKITD-OH (CPD10H) (SEQ ID NO: 1) or any pharmaceutically acceptable salt thereof
b. about 5 mM to about 50 mM of phosphate buffer component; and
c. about 190 mM to about 240 mM of one or more tonicity agent,
wherein said one or more tonicity agent comprises or consists of mannitol, wherein said composition further comprises a solvent, and
wherein said composition has a pH of about pH 6.0 to about pH 8.2.
2 . The isotonic parenteral pharmaceutical composition of claim 1 , wherein the mannitol is D-mannitol.
3 . The isotonic parenteral pharmaceutical composition according to claim 1 , wherein said buffer component is a sodium phosphate buffer.
4 . The isotonic parenteral pharmaceutical composition of claim 3 ,
wherein said sodium phosphate buffer is
disodium phosphate,
sodium dihydrogen phosphate, or
a combination thereof.
5 . The isotonic parenteral pharmaceutical composition of claim 1 , wherein the osmolality of the composition is about 230 mOsmol/kg to about 370 mOsmol/kg.
6 . The isotonic parenteral pharmaceutical composition of claim 1 , wherein said buffer component is at a final concentration of about 20 mM, said one or more tonicity agent is mannitol at a final concentration of about 190 mM to about 240 mM and wherein the pH is between about pH 7.0 and about pH 8.0.
7 . The isotonic parenteral pharmaceutical composition of claim 1 , wherein said buffer component is at a final concentration of about 15 mM to about 30 mM, said one or more tonicity agent is mannitol at a final concentration of about 230 mM and wherein the pH is between about pH 7.0 and about pH 8.0.
8 . The isotonic parenteral pharmaceutical composition of claim 1 , wherein said one or more GLP-1/GLP-2 dual agonist, or any pharmaceutically acceptable salt thereof, is present at a concentration of about 1 mg/mL to about 15 mg/mL.
9 . The isotonic parenteral pharmaceutical composition of claim 1 , comprising a phosphate buffer at a concentration of about 15 mM to about 30 mM mannitol at a concentration of about 230 mM, water for injection and sodium hydroxide and/or hydrochloric acid for pH adjustment to a pH of about pH 8.0, wherein said one or more GLP-1/GLP-2 dual agonist is CPD1 OH or a chloride salt thereof and is present at about 2 mg/mL.
10 . The isotonic parenteral pharmaceutical composition of claim 1 , comprising a phosphate buffer at a concentration of about 15 mM to about 30 mM mannitol at a concentration of about 230 mM, water for injection and sodium hydroxide and/or hydrochloric acid for pH adjustment to a pH of about pH 8.0, wherein said one or more GLP-1/GLP-2 dual agonist is CPD1 OH or a chloride salt thereof and is present at about 10 mg/mL.
11 . The isotonic parenteral pharmaceutical composition of claim 1 ,
wherein said composition comprises 2 mg of CPD1 OH, 2.65 mg of Na 2 HPO 4 (anhydrous), 0.16 mg of NaH 2 PO 4 , 41.90 ma of D-mannitol, water for injection to make 1 mL, and sodium hydroxide and/or hydrochloric acid for pH adjustment to a pH of about pH 8.0.
12 . The isotonic parenteral pharmaceutical composition of claim 1 , wherein said composition comprises 10 ma of CPD1 OH, 2.65 ma of Na 2 HPO 4 (anhydrous), 0.16 ma of NaH 2 PO 4 (anhydrous), 41.90 ma of D-mannitol, water for injection to make 1 mL, and sodium hydroxide and/or hydrochloric acid for pH adjustment to a pH of about pH 8.0.
13 . The isotonic parenteral pharmaceutical composition of claim 1 wherein said composition has a shelf-life of at least 24 months at 5° C.
14 . The isotonic parenteral pharmaceutical composition of claim 1 wherein said composition has a chemical stability of at least about 90% after 12 months storage at 25° C.
15 . The isotonic parenteral pharmaceutical composition of claim 1 wherein said composition has a chemical stability of at least about 97% after 12 months storage at about 5° C.
16 . The isotonic parenteral pharmaceutical composition of claim 1 wherein said composition has a chemical stability of at least about 97% after 24 months storage at about 5° C.
17 . A method for improving the chemical stability of an isotonic parenteral pharmaceutical composition comprising at least about 1 mg/mL of one or more GLP-1/GLP-2 dual agonist, wherein the one or more GLP-1/GLP-2 dual agonist is Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyll-isoGlu)1QAARDFIAWLIQHKITD-OH (CPD10H) (SEQ ID NO: 1) or any Pharmaceutically acceptable salt thereof;
wherein said method comprises adding mannitol to said composition.
18 . A method for:
increasing intestinal mass, improving intestinal function, increasing intestinal blood flow, or repairing intestinal damage or dysfunction, in a subject in need thereof,
the method comprising administering to the subject the isotonic parenteral pharmaceutical composition of claim 1 .
19 . The isotonic parenteral pharmaceutical composition of claim 1 , wherein the phosphate buffer component is at a concentration from about 10 mM to about 40 mM.
20 . The isotonic parenteral pharmaceutical composition of claim 1 , wherein the composition has a pH from about pH 7.0 to about pH 8.0.
21 . The isotonic parenteral pharmaceutical composition of claim 1 , wherein the one or more tonicity agent is at a final concentration of about 230 mM.
22 . The method of claim 17 , wherein the mannitol is D-mannitol.
23 . A method for the prophylaxis or treatment of malabsorption, ulcers, short-bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease, irritable bowel syndrome, pouchitis, celiac sprue, tropical sprue, hypogammaglobulinemic sprue, mucositis induced by chemotherapy or radiation therapy, diarrhoea induced by chemotherapy or radiation therapy, low grade inflammation, metabolic endotoxemia, necrotising enterocolitis, primary biliary cirrhosis, hepatitis, fatty liver disease, or gastrointestinal side-effects of inflammatory conditions, in a subject in need thereof, the method comprising administering to the subject the isotonic parenteral pharmaceutical composition of claim 1 .
24 . A method for reducing or inhibiting weight gain, reducing gastric emptying or intestinal transit, reducing food intake, reducing appetite, or promoting weight loss, in a subject in need thereof, the method comprising administering to the subject the isotonic parenteral pharmaceutical composition of claim 1 .
25 . A method for the prophylaxis or treatment of obesity, morbid obesity, obesity-linked gallbladder disease, obesity-induced sleep apnoea, inadequate glucose control, glucose tolerance, dyslipidaemia, diabetes, pre-diabetes, metabolic syndrome or hypertension, in a subject in need thereof, the method comprising administering to the subject the isotonic parenteral pharmaceutical composition of claim 1 .